流行性感冒病毒裂解疫苗在18岁以上健康人群中应用的安全性及免疫原性研究  

Safety and immunogenicity on the formulation of trivalent split influenza vaccine among healthy people aged over 18 years

作　　者：王萍[1] 张昕伟[2] 宋宇飞[2] 殷洪博[1] 刘丽杰[1] 车雷[1] 李辉[2] 刘研[2] 陈江婷[2] 

机构地区：[1]沈阳市疾病预防控制中心,110031 [2]北京科兴生物制品有限公司

出　　处：《中华流行病学杂志》2011年第2期120-124,共5页Chinese Journal of Epidemiology

摘　　要：目的 评价流感病毒裂解疫苗安尔来福（R）的免疫原性及安全性.方法 2010年8-9月在沈阳市开展开放式临床试验,选择18～60岁及＞60岁健康成年人接种安尔来福（R）进行安全性观察,并采集受试者免疫前及免疫后21 d 血清标本,采用血凝抑制试验（HI）进行流感病毒裂解疫苗甲型H1N1、甲型H3N2及乙型3个型别抗体检测.结果 130名观察对象完成疫苗接种并进行安全性观察,其中120人完成免疫前及免疫后采血.总体不良反应发生率为2.3%（3/130）,均为全身不良反应,未出现严重不良反应.接种疫苗后21 d,成年组甲型H1N1、甲型H3N2及乙型3个型别抗体阳转率分别为82.5%、93.7%、92.1%,GMT增长倍数分别为20.2、32.0、11.4,保护率分别为92.1%、98.4%、98.4%;老年组3个型别抗体阳转率分别为89.5%、91.2%、87.7%,GMT增长倍数分别为23.9、39.8、15.1,保护率分别为93.0%、94.7%、96.5%.结论 疫苗安尔来福（R）接种后甲型H1N1、甲型H3N2及乙型3个型别抗体各项指标均超过欧盟标准,表明其免疫原性及安全性良好.Objective To evaluate the safety and immunogenicity of split influenza vaccine （Anflu（R） ）. Methods An open-labeled clinical trial was carried out in adults aged 18-60 years and elders aged over 60 years from August to September, 2010 in Shenyang, Liaoning province. One dose of split influenza vaccine was administered and adverse events were observed. Serum samples were obtained prior to vaccination and 21 days post vaccination. A/H1N1, A/H3N2 and B antibodies against influenza virus were measured using micro-hemagglutination inhibition （HI） assay. Results A total of 130 subjects were recruited and 120 paired serum samples were obtained. The overall rate of adverse events was 2.3% （3/130） and all of them with systemic reaction. No single serious adverse event was reported. 21 days after the vaccination, the sero-conversion rates of A/H1N1, A/H3N2 and B antibodies against influenza virus among adults were 82.5%, 93.7% and 92.1%, respectively. The Geometric Mean Titer （GMT） ratios were 20.2, 32.0 and 11.4, while the sero-protection rates were 92.1%, 98.4% and 98.4%, respectively. The sero-conversion rates of antibodies among elders were 89.5%, 91.2% and 87.7%, with the GMT ratios as 23.9, 39.8 and 15.1, respectively. The seroprotection rates were 93.0%, 94.7% and 96.5%,respectively. Conclusion All indexes ofA/H1N1,A/H3N2 and B antibodies exceeded the licensure criteria established by the EU Committee for Medicinal Products for Human Use,proving the trial vaccine Anflu（R） with good safety and immunogenicity.

关 键 词：流感病毒裂解疫苗 成人剂型 免疫原性 安全性 

分 类 号：R5[医药卫生—内科学] R1[医药卫生—临床医学]